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      Abstract  
 
Objective: 
Non-adherence to immunosuppressant medication (ISM) is a significant problem among renal 
transplant recipients, and is associated with an increased risk of graft rejection. The main  
aim of this study was to examine to what extent demographic and clinical variables, and self-
efficacy, perceived medication necessity, medication-related worries and transplant-related 
worries are associated with ISM adherence. 
 
Methods: 
This cross-sectional study was based on a questionnaire and an interview. In total, 39 patients 
within 1.5 years after transplantation participated in the questionnaire survey. Adherence was 
classified based on the Basel Assessment of Adherence to Immunosuppressive Medication 
(BAASIS) and a VAS scale. The Partners in Health (PIH) Scale assessed self-efficacy, the 
Beliefs about Medicines (BMQ) scale assessed perceived medication necessity and 
medication-related worries, and the Transplant-Effects questionnaire (TEQ) measured 
transplant-related worries. Statistical analyses included Fisher’s exact test, Student’s t-test, 
logistic regression and correlational analysis. Nineteen patients were interviewed about their 
experiences with ISM.  
 
Results  
Non-adherence rates of 30.8% and 20% were found, based on the questionnaire reports and 
interview survey, respectively. We did not find an association between adherence and 
demographic, clinical or psychological factors. Our interview findings suggest that non-
intentional reasons play an important role in non-adherence.   
 
Discussion 
Despite the non-significant findings of our study, there were promising effect size values for 
the variables self-efficacy and time post-transplant. Our interview findings suggested that 
forgetfulness was a major reason for non-adherence. Future studies are needed to gain a better 
understanding of these factors and possible solutions for non-intentional non-adherence.  
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          Introduction 
 
Chronic kidney disease 
Chronic kidney disease (CKD) is an increasing problem worldwide, mainly due to the 
growing problem of diabetes and hypertension, two major risk factors of CKD (Haroun et al., 
2003; Zhang & Rothenbacher, 2008). The disease is characterized by a gradual and permanent 
loss of kidney function. Healthy kidneys adequately filter waste material (e.g. creatinine) out 
of the blood and produce urine. Furthermore, they let protein and other nutrients pass through 
the blood system (American Kidney Fund [AKF], n.d.). In addition, kidneys are essential for 
the regulation of calcium and phosphorus in the blood, which are important minerals for bone 
and heart functioning. Finally, kidneys play a role in the production of red blood cells. In 
CKD, the kidneys lose their ability to adequately filter the blood, which results in the 
accumulation of waste products and extra water, and the release of protein into the urine 
(AKF, n.d.). This deterioration of the filtering system can be detected by estimating the 
Glomerular Filtration Rate (eGFR) and by measuring the albumin-creatinine ratio in the urine, 
as recommended by the National Kidney Foundation (Levey et al., 2003). Early stages of 
CKD are often asymptomatic. However, as the disease progresses, patients may experience a 
wide variety of symptoms, such as chest pain, itching, muscle cramps, nausea and shortness 
of breath (National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK], 2017). 
Several complications may accompany worsening of CKD, such as increased cholesterol and 
cardiovascular disease, bone disorders, and anemia (Levey et al., 2003; Thomas, Kanso, & 
Sedor, 2009). When patients reach end-stage renal disease (ESRD), their kidneys do not 
function anymore and renal replacement therapy (RRT) is required, which includes dialysis 
and/or transplantation (Levey et al., 2003). 
  
Renal transplantation 
Transplantation is the preferred choice of treatment for many patients with ESRD. The 
number of patients receiving a kidney transplant in The Netherlands increased from around 
650 in 2005 to approximately 1,000 in 2015 (Nederlandse Transplantatie Stichting [NTS], 
2015; Nierstichting, n.d.). Patients can receive a kidney from a deceased or living donor, of 
which the latter can be related or unrelated to the recipient. 
            Renal transplantation has shown to (temporarily) restore the patient’s health. Not 
surprisingly then, it has been associated with an improved quality of life and a reduced 
mortality risk in comparison with dialysis (Tonelli et al., 2011). Nonetheless, transplant 
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patients are faced with a number of challenges in daily life. They remain chronically ill and 
continuously have to monitor signs of graft rejection (e.g. hypertension and high levels of 
creatinine), especially during the first year after transplantation. In addition, they have to 
follow a lifelong, strict medication regimen, including immunosuppressant medications (ISM) 
that reduce the risk of graft rejection by decreasing the body’s immune response. This 
inhibition of the immune system leads to susceptibility to infections and cancer, especially 
kidney and skin cancer, and non-Hodgkin lymphomas. Other side effects are cardiovascular 
disease and osteoporosis (Hsu & Katelaris, 2009; Kasiske, Snyder, Gilbertson, & Wang, 
2004). Despite these side effects, ISM is of vital importance for the patient’s health. However, 
these medicines can only reduce the risk of graft failure when the patient precisely adheres to 
the regimen, that is when dose and timing are correct. Even small deviations from the 
medication regimen lead to an increased risk of graft rejection (De Geest et al., 1998). It was 
found that around 20% of kidney transplant patients does not adhere to their regimen 
(Prendergast & Gaston, 2010). This rate is higher than among any other group of solid organ 
transplant recipients (Dew et al., 2007). This number is alarming, considering that the major 
cause of both acute and chronic graft failure is medication non-adherence (Prendergast & 
Gaston, 2010). A meta-analysis of Butler, Roderick, Mullee, Mason and Peveler (2004) 
revealed that renal transplant patients who do not entirely adhere to their medication regimen, 
have a 7 times higher risk of graft failure. A median of 36% of graft losses could be traced 
back to medication non-adherence. Graft loss leads to increased hospitalizations and costly 
anti-rejection therapies (Denhaerynck, 2005; Prendergast & Gaston, 2010). Therefore, it is of 
great importance to understand the factors that influence medication adherence in this patient 
group. 
 
Medication adherence     
According to the World Health Organization [WHO] (Sabaté, 2003, p. 3), adherence is the 
extent to which a person’s behaviour – taking medications, following a recommended diet 
and/or executing life-style changes – corresponds with the agreed recommendations of a 
health care provider. Medication non-adherence can be defined as deviation from the 
prescribed medication regimen sufﬁcient to inﬂuence adversely the regimen’s intended effect 
(Fine et al., 2009, p. 36).  
    There are several methods to measure medication adherence, such as pill count, 
checking levels of agents in the blood, and electronic monitoring of the opening of the 
pillboxes (Denhaerynck et al., 2005). Patient self-report is recommended as primary 
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methodology in clinical practice, and is considered the most convenient and cost-effective 
method (Osterberg & Blaschke, 2005; Weng, Yang, Huang, Chiang, & Tsai, 2017). Self-
report is an essential component of adherence assessment and is often combined with the 
abovementioned methods (Schäfer-Keller, Steiger, Bock, Denhaerynck, & De Geest, 2008).  
However it has to be noted that self-report measures have several limitations, such as response 
bias (e.g. the tendency of a respondent to give certain answers, or to respond in a social 
desirable manner) and the fact that scales are interpreted in different ways (Stirratt et al., 
2015). Despite these drawbacks, self-report is a well-validated measure that allows to 
determine medication beliefs and barriers to adherence (Lam & Fresco, 2015).  
  
Determinants of medication adherence  
The WHO describes five dimensions that are important in predicting adherence to long-term 
therapy in patients with chronic disease, namely sociodemographic, condition- and therapy 
related factors (i.e. clinical factors), patient-related factors (e.g. psychological factors), and 
factors on the level of the health-care system (Sabaté, 2003). This study focused on 
sociodemographic, clinical and psychological variables, as identifying risk factors for non-
adherent behaviour helps to predict which subgroups of patients need extra support with 
medication use in the clinical setting. 
  Some review articles have addressed the predictive value of sociodemographic factors 
on adherence (DenHaerynck et al., 2005; Rebafka, 2016). Age has been associated with 
adherence to ISM in the kidney recipient population. Most studies have found that younger 
patients (both adolescents and young adults) show more non-adherent behaviour than older 
patients. Adherence seems to gradually increase with age. There are inconclusive findings 
with regard to the relation between ISM adherence and educational level (Denhaerynck et al., 
2005; Rebafka, 2016). However, in other patient populations, high educational level has been 
identified as a positive predictor of adherence to therapy (Jackson, Leclerc, Erskine, & 
Linden, 2005). Finally, studies have found no consistent association between gender and 
adherence (Denhaerynck et al., 2005; Rebafka, 2016). 
  Regarding clinical variables, several studies suggested that as time increases from 
transplantation, non-adherence continuously increases as well (De Geest et al., 2014; Weng et 
al., 2017). This may be explained by the fact that patients become accustomed to their 
stabilized condition and underestimate the importance of ISM for their health (Weng et al., 
2017). On the level of treatment, complexity of the medical regimen plays an important role. 
More specifically, there is some evidence that frequent dosing (i.e. more than one dose per 
6 
 
  
day) and a high amount of pills per dose increase the risk of non-adherence among kidney 
transplant recipients (Constantiner & Cukor, 2011; Morales & Lázaro, 2012).  
  The current study aimed to contribute to the existing research on the role of previously 
sociodemographic and clinical factors in medication adherence. 
  Psychological factors           
  Previous research in different patient populations has shown that certain beliefs and 
concerns are associated with medication adherence. This study focused on self-efficacy, 
medication beliefs and concerns about transplant rejection, as these factors are modifiable and 
therefore relevant for clinical practice.  
  Self-efficacy 
 Self-efficacy is one of the most important predictors of health-promoting behaviours (Sabaté, 
2003). As described by Bandura (1977) self-efficacy is an individual’s confidence in his/her 
own abilities to successfully solve problems or complete tasks. In the context of chronic 
disease, these tasks are related to self-management, which involves managing symptoms and 
signs of illness, the impact of illness on daily functioning, and adhering to treatment regimens 
(Lorig & Holman, 2003). People who are more confident about their ability to manage their 
health, are more likely to perform recommended health-promoting behaviours, as the Health 
Belief Model states (Rosenstock, 1974).  
  In a study of Williams et al. (2009), it was found that enhancing self-efficacy 
regarding disease management in patients with diabetes, led to better adherence and physical 
health. In a more recent study of Maeda, Shen, Schwarz, Farrell and Mallon (2013) on 
medication adherence in heart failure patients, self-efficacy also appeared to be a strong 
predictor of adherence to the treatment for hypertension. In addition, they found that self-
efficacy plays a mediating role in the relation between depression and adherence. Patients 
with depressive symptoms may doubt about their abilities to manage their condition, as they 
have negative self-esteem and low perceived control, which places them at risk for non-
adherence (Maeda et al., 2013). Among kidney transplant recipients, self-efficacy has also 
shown to be essential for self-care practice (Weng, Dai, Huang, & Chiang, 2010). Lower self-
efficacy has been identified as a major risk factor for non-adherence and self-care behaviours 
in this patient group (Denhaerynck et al., 2007; Silva et al., 2016; Wierdsma, Van Zuilen, & 
Van der Bijl, 2011). A cohort study of Massey et al. (2013) showed that the perceived ability 
to take ISM (i.e. self-efficacy) among renal transplant recipients decreased over a period of 6 
months.  
  Several methods aiming at modifying self-efficacy among kidney transplant recipients 
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have been described, such as setting short-term goals and developing mastery experiences in 
taking medication consistently, using role modelling and discussing negative effects of the 
medicines (De Geest et al., 2006). 
 
  Medication-related beliefs 
  According to the necessity-concerns framework of Horne (2003), an analysis in which 
benefits of medications are weighed against perceived barriers influences individual’s 
decisions about adherence. Medication beliefs consist of two categories: perceived need for 
treatment and concerns about the negative effects of medication. According to Horne (2003), 
these variables should be integrated in Leventhal’s Common Sense Model to explain 
adherence behaviour. This model proposes that illness stimuli trigger cognitive and emotional 
representations about the illness which indirectly influence the management of illness threat 
via coping strategies (Leventhal, Brissette, & Leventhal, 2003). According to Horne (2003), 
representations about treatment are processed in the same manner: cognitive representations 
about treatment (e.g. perceived necessity of treatment) and emotional representations about 
treatment (e.g. concerns about side-effects), influence one’s coping procedure 
(adherence/non-adherence). Another model in which medication-related beliefs are integrated, 
is the Health Belief Model. According to this model, the likelihood of an individual to engage 
in a recommended health-related behaviour (e.g. adhering to medication), is influenced by 
perceived benefits and barriers of this behaviour (Rosenstock, 1974). Medication beliefs can 
be seen as a barrier to adherence, when patients perceive medication to be unnecessary and to 
cause too many unwanted effects.  
  In several patient populations, such as patients with rheumatoid arthritis and HIV,  
it has been shown that people who hold stronger beliefs with regard to the necessity of their 
medication and who are less concerned about their therapy, show better adherence (Treharne, 
Lyons & Kitas, 2004; Gonzalez et al., 2007). Among renal transplant patients, attitudes 
towards medication also seem to predict adherence. A study of Griva et al. (2012) suggested 
that lower perceived medication necessity is associated with higher risk of non-adherence, as 
they attach lower priority to taking medication, and are consequently more likely to forget it.  
Concerns about the negative effects of ISM has been negatively associated with adherence 
(Weng et al., 2017). Tielen et al. (2014) performed a longitudinal study, which demonstrated 
that concerns regarding medication of renal transplant recipients were associated with non-
adherence. Several studies have shown that higher perceived necessity of medication and 
lower worries about negative effects predict ISM adherence among renal transplant recipients 
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(Chisholm-Burns, 2012; Kung et al., 2012). Others (Lennerling & Forsberg, 2012; Massey et 
al., 2013) have not found associations between medication beliefs and adherence. Butler, 
Peveler, et al. (2004) demonstrated that perceived need for ISM was an important predictor of 
medication adherence in a sample of renal transplant recipients. However, concerns about 
medication showed no significant correlation with medication adherence, which contradicts 
previously mentioned findings (Chisholm-Burns, 2012; Kung et al., 2012). The authors stated 
that this might be explained by the higher impact of transplant-related fear that surpasses the 
fear of concerns about side effects of the medication (Butler, Peveler, et al., 2004). They 
suggested that this concept of transplant-related fear should be further investigated.  
  Some strategies aiming to improve adherence via medication beliefs have been 
described, such as tailoring the information about medications to the patient’s personal 
situation and information needs. For example, healthcare providers can assess to which degree 
a patient is aware of the risks of non-adherence, and can consequently adapt the information. 
Linn, Van Weert, Van Dijk, Horne and Smit (2016) suggested that this strategy may help 
patients to recognize the importance of ISM and to reduce their concerns about side effects 
(Linn et al., 2016). 
  Transplant-related worries 
  Individuals who feel more susceptible to losing their transplant, may be more 
adherent, in line with the Health Belief Model (Rosenstock, 1974). Worries about rejection of 
the transplant are a major stressor among renal transplant recipients (Fallon, Gould, & 
Wainwright, 1997; Griva et al., 2002; Kong & Molassiotis, 1999; Nilsson, Forsberg, 
Bäckman, Lennerling, & Persson, 2010; Nilsson, Persson, & Forsberg, 2008). Patients tend to 
be especially anxious during the first year after transplantation, as they are aware of the higher 
risk of graft rejection during this period (Fallon, Gould, & Wainwright, 1997). To the best of 
our knowledge, only two studies examined the relation between transplant-related worries and 
adherence. A qualitative study of Orr et al. (2007) showed that fear about transplant rejection 
is a motivational factor for adherence. In a more recent, cross-sectional study of Griva et al. 
(2012), patients who worried less about viability of the transplant showed significantly more 
non-adherence. In line with the results of Orr et al. (2007) the authors suggested that high 
transplant-related worries in combination with high perceived medication necessity may 
motivate patients in daily medication-taking (Griva et al., 2012). This study aimed to further 
investigate the relation between transplant-related worries and adherence.  
Moreover, we were interested in the relation between medication-related worries and worries 
about transplant rejection. Worry has been defined as a chain of thoughts, negatively affect-
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laden and relatively uncontrollable (Borkovec, Robinson, Pruzinsky, & DePree, 1983, p. 10). 
A distinction has been made between trait worry and state worry. Trait worry is the stable 
tendency to worry about a wide range of actual and potential negative events (i.e. generic 
worry), whereas state worry is the situation-specific worry in daily life (Versluis, Verkuil, & 
Brosschot, 2016). A study of Verkuil, Brosschat and Thayer (2007) showed that trait worry 
significantly predicts daily/state worry. In a recent study of Leal, Goes, Da Silva and Teixeira-
Silva (2017) evidence was found for the unidimensional approach of anxiety, which states 
that there is a general trait anxiety which predisposes individuals to higher state anxiety across 
various situations in daily life. Considering these findings, it is logical to assume that different 
domains of daily worry are highly correlated. 
 
Aims of this study 
A wide variety of factors has been associated with adherence to ISM. Several 
sociodemographic and clinical variables have been identified as risk factors for non-
adherence. Higher self-efficacy and perceived need for ISM and lower medication-related 
worries seem to predict better adherence. However, results regarding the role of these 
psychological factors are still inconsistent and further research is needed. Furthermore, the 
association between transplant-related worries and adherence, and its relation with 
medication-related worries, is yet unclear.    
  This study aimed to add to existing research and consisted of two parts, a quantitative 
and a qualitative part (a questionnaire and a semi-structured interview, respectively). 
Regarding the quantitative part of this study, we aimed to classify and describe self-reported 
medication adherence across a sample of renal transplant recipients within 1.5 years after 
transplantation. Another goal was to compare adherent and non-adherent patients on 
sociodemographic, clinical and psychological factors to determine both modifiable and non-
modifiable risk factors. In addition, we focused on the relation between ISM adherence and 
self-efficacy, medication beliefs and transplant-related worries in renal transplant recipients. 
Finally, the relation between medication- and transplant-related worries was examined.  
Based on previous research, we assumed that participants who scored high on medication-
related worries, would also score high on transplant-related worries, and vice versa.  
The following research questions and hypotheses were formulated: 
 
Research question 1: Are there differences between adherent and non-adherent renal 
transplant recipients on sociodemographic, clinical and/or psychological factors? 
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  Hypothesis 1: Higher age and educational level, less months post-transplant, lower
 complexity of the ISM regimen will be significantly associated with being classified as
 adherent. 
  Hypothesis 2: Gender will not be significantly related to adherence classification.  
   Hypothesis 3: Self-efficacy will be significantly higher among adherent patients than
 among non-adherent patients.  
  Hypothesis 4: Perceived medication necessity will be significantly higher among
 adherent patients than among non-adherent patients.    
 Hypothesis 5: Medication-related worries will be significantly lower among adherent
 patients than among non-adherent patients.  
   Hypothesis 6: Transplant-related worries will be significantly higher among adherent
 than among non-adherent patients.        
 Hypothesis 7: The combination of higher self-efficacy, higher perceived medication
 necessity, lower medication-related worries and higher transplant-related worries will
 significantly predict adherence classification. 
Research question 2: What is the relation between medication-related and transplant-related 
worries? 
  Hypothesis 8: There will be a significant, positive correlation between medication
 related and transplant-related worries.  
 
With regard to the qualitative part of this study, our goal was to acquire more in-depth 
information about patients’ experiences with the ISM regimen, and the relation between 
adherence and beliefs regarding medication and the graft. In addition, we wanted to explore 
additional reasons for medication (non-)adherence from the patient perspective that were not 
integrated in the questionnaire. Therefore, the following research question was addressed: 
 
Research question 3: What is the patient perspective on medication adherence, and how do 
medication- and transplant-related beliefs and worries play a role in this?  
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        Methods 
 
Study design 
This study was based on a cross-sectional design, to examine the relationships between the 
outcome variable adherence classification and sociodemographic, clinical factors and the 
psychological factors self-efficacy, perceived medication necessity, medication-related 
worries, and transplant-related worries. Data were acquired as part of the Medical Dashboard 
project at the Leiden University Medical Center (LUMC). The Medical Dashboard is an e-
health application system that allows patients to be more involved in their own disease and 
therapy process. This systems provides patients with an overview of their self-monitored 
values (e.g. blood pressure, weight) and hospital data (medication, laboratory results).  
 
Participants 
Between March and June 2016, renal transplant patients from the Leiden University Medical 
Center (LUMC) who had an appointment at the outpatient clinic during this period received 
an invitation letter for instructions about the Medical Dashboard project. The inclusion criteria 
for this study were sufficient mastery of the Dutch language and having had a relatively recent 
transplantation ( < 1.5 years), as risk of graft rejection is highest during this period.  
  For the qualitative part of the study, another sample of patients was approached for an 
individual, semi-structured interview including questions about the role of ISM in their daily 
lives, worries about the effects of these medicines and about the risk of graft rejection.  
A random selection of patients was made from the outpatient clinic appointment system 
during 3 weeks, using the same inclusion criteria as described above. Patients with a 
transplantation > 1.5 years were excluded from the list. Of the remaining patients, the first, 
third and fifth on the list was repeatedly selected. This group received an invitation letter with 
information about the aim of the interview and were requested to send an email if they were 
willing to participate. They were called one week afterwards if they did not respond yet, 
which was announced in the letter. 
 
Procedure 
During the recruitment period, renal transplant recipients who received instructions about the 
Medical Dashboard project after attending their routine appointment with the nephrologist, 
and who met the inclusion criteria, were asked to participate in this study. No formal ethical 
approval was needed for this study as determined by the medical ethics committee of the 
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hospital. On site, patients were informed by the instructors about the objectives of the study, 
and those who were willing to participate received a questionnaire that they could return in a 
pre-stamped envelope. The instructors were fourth- and fifth-grade medical students from 
Leiden University. A consent form was attached to the questionnaire. Patients who did not 
return the questionnaire after 2 weeks, received a reminder by email. 
 The interviews were conducted by a medical and a psychology student at the 
outpatient clinic of nephrology. The interviewers explained the aim and the length of the 
interview and obtained written conformed consent from all participants. The interviews were 
digitally recorded and notes were taken during the sessions by the interviewer. Afterwards, 
the recordings were transcribed verbatim.  
 
Instruments 
  Questionnaire  
  Sociodemographic and clinical data were gathered for the description of the sample 
and analyses. We used amount of ISM medications per day (one vs. more than one) and 
amount of ISM pills per day as a measure of the complexity of the ISM regimen (Muir, 
Sanders, Wilkinson, & Schmader, 2001). Participants were asked to list their marital status 
(single, married, living with a partner) and education level (low vs. high) in the questionnaire. 
Other factors (age, gender, months post-transplant, type of transplant, pre-dialysis, creatinine 
serum levels, eGFR, amount of ISM) were gathered from the patients’ medical files in the 
LUMC. 
  Medication adherence was inquired by using the Basel Assessment of Adherence to 
Immunosuppressive Medication (BAASIS), designed by the Leuven-Basel research group 
Institute of Nursing Science University of Basel (2009). This scale consists of three questions 
about missing, timing and dose of medication. These questions are “Can you remember to 
have missed a dose of immunosuppressant medications over the last 4 weeks?”, “Can you 
remember to have taken your immunosuppressant medications more than 2 hours before or 
after the prescribed time over the last 4 weeks?”, and finally “Did you change the amount of 
your immunosuppressant medications without prescription of the doctor over the last 4 
weeks?” These questions have two response categories (yes/no), and five subcategories, 
namely one time, two times, three times, four times, and more than four times. A visual 
analogue scale (VAS) ranging from 0 (never take medication as prescribed) to 100 (always 
take medication as prescribed) was added to let patients rate how well they have taken their 
ISM in the past 4 weeks. For analysis, a dichotomized score (adherent vs. non-adherent) was 
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used. A positive answer to any BAASIS-item and/or a score of <95 on the VAS scale was 
categorized as non-adherent, as established by previous studies (e.g. Lennerling & Forsberg, 
2012). 
  Self-efficacy regarding disease self-management skills was measured with the Partners 
In Health (PIH) Scale. This scale was originally used in the Flinders Program of Chronic Care 
Self-Management (Battersby, Ask, Reece, Marwick, & Collins, 2003). It consists of 13 items, 
such as “I have a clear understanding of my kidney disease”, “I have the ability to share in 
decisions made about the treatment of my kidney disease”, “I use my medications as directed 
by the doctor”, and “I understand what to do when my symptoms get worse”. Participants 
rated how much they agreed with these statements on a nine-point scale, ranging from the 
category responses 1=‘very poor’ to 9=‘very good’. In this study, the average of all items was 
used as a total score. Petkov, Harvy and Battersby (2010) reported that the PIH-scale has a 
good internal consistency with a Cronbach’s alpha coefficient of 0.82. In the current sample, a 
Cronbach’s alpha coefficient of .93 was found. 
  Beliefs about ISM were assessed with the Necessity scale and the Worry scale of the 
Beliefs About Medicines Questionnaire (BMQ) - Specific, developed by Horne, Weinman 
and Hankins (1999). The Necessity scale consists items such as “Without my medications I 
would be very ill” and “My future health depends on my medications”. Some exemplar items 
of the Worry scale are “I sometimes worry about the side effects these medications can have 
on the longer term” and “My medications disrupt my life”. The items are based on a five-
point Likert scale, ranging from 1=‘strongly agree’ to 5=‘strongly disagree’. For the analyses, 
scores were reversed so that higher scores indicate higher levels of worry, and higher levels of 
perceived necessity. The average score per scale was used. Cinar et al. (2016) reported that 
the Necessity and Concerns scales have an acceptable internal consistency in a Turkish patient 
population, with a Cronbach’s alpha coefficient of .81 and .67, respectively. In the current 
sample, these values reached .86 and .72.  
   Finally, transplant-related worries were assessed with the Worry scale of the 
Transplant Effects Questionnaire (TxEQ), designed by Ziegelmann et al. (2002). The scale 
consists of 6 items, such as “I am worried about damaging my transplant”, “I keep wondering 
how long my transplant will work”, and “I worry each time my anti-rejection drug regime is 
altered by my doctor”. A five-point Likert scale was used, ranging from 1=‘strongly agree’ to 
5=‘strongly disagree’. For the analyses, scores were reversed so that high scores indicate high 
levels of worry. The average of all items on the scale was used as a total score. The authors 
reported that this scale has a good internal consistency, with a Cronbach’s alpha coefficient of 
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.81. In our sample, a similar Cronbach’s alpha coefficient was found. 
 
   Interview       
  The semi-structured interview included questions regarding attitudes towards specific 
eHealth-functions and experiences with the Medical Dashboard, which do not fall into the 
scope of this study. Specific questions were added that covered the same themes/concepts as 
the questionnaire, namely the role of ISM in daily life, worries about the effects of these 
medicines and about the risk of graft rejection. The following questions were used: 
  1. What role does the ISM regimen play in your daily life?  
  2. Do you use strategies to integrate ISM intake into your daily routine? 
  3. To what extent do you believe you need your ISM? 
  4. Did you experience any side effects of the ISM? Do you worry about (possible) side 
  effects? If patient experiences side effects: how do you weight these side effects to the
 positive effects of the ISMs?     
  5. Do you sometimes worry about the risk of graft rejection? If yes: do these concerns 
  influence your daily ISM intake? 
 
Statistical analyses  
Statistical analyses were performed with IBM Statistical Package for the Social Sciences 
(SPSS), version 23.0. Statistical significance was set at p < .05. Firstly, descriptive statistics 
were calculated and distributions of all variables were analysed. 
 To compare sociodemographic and clinical variables of the adherent and non-adherent 
group, Fisher’s exact test and student t-test were used. Subsequently, independent-sample t-
tests were performed to examine the relationships between adherence and the independent 
variables – self-efficacy, perceived medication necessity, medication-related worries and 
transplant-related worries. Before executing the t-tests, normality and homogeneity of all 
factors were evaluated with the Kolmogorov-Smirnov test and the Levene’s test, respectively.  
In order to explore if the combination of psychological factors is related to medication 
adherence, a multiple logistic regression analysis was used. The assumption of collinearity 
was tested by examining intercorrelations and variation inflation scores (VIF’s). Linearity of 
the logit was tested by Box-Tidwell test. In addition, it was assured that there were no less 
than 10 participants per independent variable, as a higher number of events per value (EPV) 
can lead to less reliable results due to overfitting (Peduzzi, Concato, Kemper, Holford, & 
Feinstein, 1996). In this sample, an amount of four independent variables was allowed to be 
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included in the model. Self-efficacy, beliefs regarding necessity of medication, medication-
related worries, and transplant-related worries were the independent variables, and medication 
adherence was the dichotomous, binary outcome variable. In the regression model, self-
reported adherence was the dichotomous, binary outcome. Finally, to explore the relationship 
between medication- and transplant-related worries, correlation analysis was used. 
  Due to the small sample size, we looked at Cohen’s d effect size to examine the 
strength of the results. This value is independent of sample size (Sullivan & Feinn, 2012). We 
used the Power Analysis and Sample Size Software (PASS version 14) to determine the 
statistical power in relation to the sample size.  
  Concerning the qualitative data in the second part of the study, thematic analysis was 
used to explore the participants’ response patterns. This is a widely used method to discover 
response patterns in qualitative study results (Braun & Clarke, 2006). One person analysed the 
notes and recordings to identify themes and typical responses. The number of participants 
who reported non-adherence and side effects was counted.  
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      Results 
 
Results questionnaire  
 
Description of the sample 
In total, 59 participants were recruited. All of them consented to participate in this study, but 
only 42 filled out the questionnaire (response rate 71.0%). In three cases among these 42 
(7%), one or more scales on the list were left blank. These cases were not included in this 
study. The final sample thus consisted of 39 participants. Approximately 60% of the sample 
was male. The age of the sample ranged from 28 to 74 years (M = 56.41, SD = 12.63).  
The majority of the participants was married or living together (70%) and completed lower 
education (71.8%). Months post-transplant ranged from 0 to 18 (M = 5.97, SD = 5.10).  
The majority of patients received a transplant from a living donor (64%). The number of 
patients who had received dialysis before and those who received transplantation as primary 
therapy, was approximately equal (51% and 44%, respectively). The estimated glomerular 
filtration rate (eGFR) had an average of 47.14 (SD = 17.82), which is classified as a mild to 
moderate impairment of renal function. Finally, the typical medication regimen consisted of 2 
ISM medications and 4 pills per day. The sociodemographic and clinical characteristics of the 
sample are presented in Table 1. 
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Table 1 
Descriptive statistics for sociodemographic and clinical variables (n = 39)                                                                
Variable n (%) Range 
Gender  
   Male 
   Female 
   Unknown 
 
23 (59.0) 
14 (35.9) 
2 (5.1) 
 
 
Age – M (SD) 
 
Marital status 
   Single 
   Married/living together 
   Separated/divorced/widowed 
    
 
56.41 (12.64) 
 
 
12 (30.8) 
27 (69.2) 
0 
 
28-74 
Educational level 
   Lower education 
   Higher education 
    
 
Months post-transplant – M (SD) 
 
Type of transplant    
   Deceased 
   Living 
   Unknown 
 
Dialysis prior to transplantation 
   Yes 
    No 
    Unknown    
 
Serum creatinine level – M (SD) 
 
eGFR – M (SD) 
 
ISM medications per day – M 
(SD) 
 
ISM pills per day – M (SD) 
 
28 (71.8) 
11 (28.2) 
 
 
5.97 (5.10) 
 
 
 
9 (23.1) 
25 (64.1) 
5 (12.8) 
 
 
20 (51.3) 
17 (43.6) 
2 (5.1) 
 
139.97 (46.79) 
 
47.14 (17.82) 
 
1.78 (.53) 
 
 
4.49 (1.57) 
 
 
 
 
 
0-18 
 
 
 
 
 
 
 
 
 
 
61-272 
 
0-90 
 
1-3 
 
 
2-8 
      
Note: M = mean, SD = standard deviation, n = number of participants. 
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Self-reported medication adherence 
Table 2 summarizes the adherence characteristics of the sample. Patients were classified as 
non-adherent when they reported non-adherence on any of the BAASIS items and/or the VAS 
score. Of the total sample, 12 participants (30.8%) were classified as non-adherent in the past 
4 weeks. Of these patients, 7 only reported non-adherence on the BAASIS scale; 3 only on the 
VAS scale, and 2 patients reported non-adherence on both scales. Of non-adherence on the 
BAASIS items, 63.6% was related to timing, 27.3% to missing, and 9.1% to dosing of 
medication.  
 
Table 2  
Descriptive statistics for self-reported medication adherence                                                              
a A VAS score of < 95 was classified as a non-adherent response. 
b  Patients were classified as non-adherent when they reported any form of non-adherence on the 
BAASIS items and/or the VAS score. 
 
Description of demographic, clinical and psychological variables 
Participants reported their self-efficacy regarding disease management with an average of M = 
7.47 (SD = 1.12; possible range is 1-9). Our sample held strong beliefs about the necessity of 
their ISM (M = 4.28, SD = .68; possible range is 1-5). Overall, their beliefs about the 
worrisome aspects of ISM were neutral (M = 2.85, SD = .76; possible range is 1-5).  
 
Adherence item 
Response 
n (%) 
Categorized as non-adherent  
n (%) 
1. Do you remember missing a dose 
of ISM in the past 4 weeks?  
(i) once 
2. Do you remember taking ISM 
more than 2 hours before or after the 
prescribed dosing time in the past 4 
weeks? 
(i) once 
(ii) 2-3 times 
(iii) 4-5 times 
3. Have you altered the prescribed 
amount of IM during the past 4 
weeks without your doctor telling 
you to do so? 
(i) yes     
 
VAS score < 95 
 
Dichotomous adherence score 
 
 
3 (7.7) 
 
 
 
 
4 (10.3) 
2 (5.1) 
1 (2.6) 
 
 
 
 
1 (2.6) 
 
     
 
 
3 (7.7) 
 
 
7 (18.0) 
 
 
 
 
 
 
1 (2.6) 
 
 
 
5 (12.8)a 
 
12 (30.8)b 
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In general, patients perceived some concerns regarding their transplant (M = 3.39, SD = .86; 
possible range is 1-5). 
  The continuous variables were explored on normality, linearity, homogeneity of 
variances, and multicollinearity, for possible violations of the assumptions for t-tests and 
logistic regression analysis. The distributions of age and months post-transplant did not have 
outliers; the distribution of amount of ISM pills per day did have a considerable number of 
outliers (7). Among the psychological variables, there were three identifiable outliers on the 
self-efficacy scale and one on the medication-related worries scale. However, as these were 
no extreme values, they were included in the analyses. Normality of distribution was 
evaluated by visually inspecting the histograms, examining measures of skewness and 
kurtosis and the Kolmogorov-Smirnov test. Amount of ISM pills per day was not normally 
distributed, with p < .001 at the Kolmogorov-Smirnov test. Therefore, it was decided not to 
include this variable in the analyses. Among the psychological variables, only perceived 
medication necessity significantly deviated from normality. However, due to the small sample 
size we decided to continue with the analysis without executing transformations. In order to 
check for multicollinearity, intercorrelations between the independent variables and VIFs 
were examined. No values of Pearson’s r > .70 between the independent variables were found 
and all VIFs had an acceptable value (< 2), which indicates that there were no 
multicollinearity issues. The assumption of linearity of the logit was met, as interactions 
between the independent variables and their logs were not significant when including them in 
the regression model.  
 
Adherence classification and sociodemographic and clinical variables 
The adherent and non-adherent participants were compared on age, educational level, months 
post-transplant, and amount of ISM types. There was no significant difference in age between 
non-adherent (M = 55.09, SD = 13.89) and adherent patients (M = 56.96, SD = 12.32),   
t(35) = .41, p = .687. The effect size for age was very small, d = .14. Months post-transplant 
did not differ significantly between non-adherent (M = 7.00, SD = 6.12) and adherent patients 
(M = 5.54, SD = 4.66), t(34) = -1.15, p = .432. However, there was a medium Cohen’s d 
effect size value of .42, which indicates that the result has a medium strength. There was no 
significant relation between non-adherent and adherent participants in amount of ISM 
medications (one vs. more than one), p =.442, two-tailed Fisher’s exact test, Cramer’s  
V = .137. There was no significant difference between adherent and non-adherent patients on 
educational level, p = .736, Fisher’s exact test, Cramer’s V = .076. Taking these results 
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together, hypothesis 1 was rejected. Finally, there were no significant differences between 
adherent and non-adherent patients on gender (p = .150) confirming hypothesis 2. 
  In conclusion, comparing demographics and clinical features of adherent and non-
adherent participants, no statistically significant differences were found.  
 
Adherence classification and psychological variables  
Independent sample t-tests were conducted in order to compare the non-adherent and adherent 
group on the psychological variables. No significant differences were found between non-
adherent (M = 7.14, SD = 1.26) and adherent patients (M = 7.62, SD = 1.05) on self-efficacy 
scores, t(37) = 1.24, p = .222. Therefore, hypothesis 3 was rejected. Further, Cohen’s d effect 
size was .43, which is close to a medium effect. With regard to medication necessity, there 
were no significant differences between non-adherent (M = 4.32, SD = .59) and adherent 
participants (M = 4.27, SD = .73), t(37) = -.21, p = .835. Consequently, hypothesis 4 was 
rejected. In addition, a very small effect size of d = .07 was found. Similar results were found 
for medication-related worries; there were no significant differences between non-adherent 
(M = 2.93, SD = .70) and adherent patients (M = 2.81, SD = .80) on medication-related 
worries, t(37) = -.45, p = .652. Thus, hypothesis 5 was rejected. As with medication necessity, 
the effect size value was small (d = .16). 
The differences between the non-adherent group (M = 3.41, SD = .97) and the adherent group 
(M = 3.38, SD = .82) on transplant-related worries was not significant either, t(37) = -.16,  
p = .895, therefore rejecting hypothesis 6. The effect size was very small, d = .06.  
A summary of the group comparisons is depicted in Table 3. 
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Table 3 
Group differences for the independent variables 
 
 
Associations between the independent variables and adherence 
Binary logistic regression analysis using the Forced entry method was conducted to determine 
the strength of self-efficacy, perceived medication necessity, medication-related worries and 
transplant-related worries in predicting adherence group classification (adherent vs. non-
adherent). This analysis showed that self-efficacy (odds ratio [OR], 1.57; 95% CI, .76-3.24;  
p = .223), medication necessity (OR, .76; 95% CI, .24-2.36; p = .632), medication-related 
worries (OR, 1.11; 95% CI, .37-3.31; p = .850) and transplant-related worries  
(OR, 1.10; 95% CI, .45-2.57; p = .879) were not significantly reliable in distinguishing 
between adherent and non-adherent patients. These coefficients are presented in Table 4. 
The model explained 6.3% of the variance in outcome (χ2= 1.77, P =.77). The model correctly 
classified 71.8% of the cases, compared to 69.2% in the null model. Based on these outcomes, 
hypothesis 7 was rejected.  
 
 
 
Variable 
t-test for equality of means    
 
M (SD) Range t (df) p Cohen’s d 
 
Self-efficacy 
   Adherent 
   Non-adherent 
 
 
7.62 (1.05) 
7.14 (1.26) 
 
 
5-9 
4.38-8.62 
 
 
1.24 (37) 
 
 
.222 
 
 
.43 
      
Med. Necessity 
   Adherent 
   Non-adherent 
 
 
4.27 (.73) 
4.32 (.59) 
 
2.80-5 
3-5 
 
-.21 (37) 
 
 
 
.835 
 
.07 
Med. Worries 
   Adherent 
   Non-adherent 
 
 
2.81 (.80) 
2.93 (.71) 
 
 
1.17-4 
11.83-
4.33 
 
-.45 (37) 
 
 
 
.652 
 
 
.16 
Trans. Worries 
   Adherent 
   Non-adherent 
 
 
3.38 (.82) 
3.42 (.97) 
 
2.17-5 
1.83-4.83 
 
-.13 (37) 
 
.895 
 
.04 
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Table 4 
Regression coefficients 
 B (SE) Wald p 95% CI for Odds Ratio 
    Lower     Odds ratio      Upper 
Self-efficacy .45 (.37) 1.483 .223                           .76              1.57             3.24 
Medication 
necessity 
 
-.28 (.58) 
 
.229 
 
.632 
 
  .24              .76              2.36 
Medication-related 
worries 
 
.11 (.56) 
 
.036 
 
.850 
 
   .37              1.11            3.31 
Transplant-related 
worries 
 
Constant 
 
.07 (.45) 
 
-1.87 (4.02) 
 
.023 
 
.215 
 
.879 
 
.643 
 
   .45              1.10            2.57 
Note. R2 = .03 (Hosmer & Lemeshow), .04 (Cox & Snell), .063 (Nagelkerke), Model Goodness-of-
Fit  x2 (4) = 1.77 , p > .05. 
  
 
Relation between medication- and transplant-related worries 
A Pearson product moment correlation was computed to assess the relationship between 
medication-related worries and transplant-related worries. There was a non-significant 
relation between the two variables, r = .30, p = .065. Therefore, hypothesis 8 was not 
accepted.  
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Results interview  
 
Description of the sample 
In total, 28 patients were invited for the interview. Of these, 19 consented to participate. Four 
participants dropped out due to cancelled hospital appointments and bad physical conditions. 
The subsample consisted of 15 patients, of whom 60% was male. The average age of this 
group was 55.31 (SD = 9.92) and ranged from 44 to 77. 
 
Outcomes 
Firstly, the participants were asked about the importance of ISM in their life. All patients 
emphasized the importance of adherence for the functioning of their graft. Reasons for 
adherence that were mentioned, were being responsible for one’s own health, feelings of 
gratitude towards the donor, and avoiding to go back on dialysis. Avoiding kidney failure was 
the most frequently reported reason for adherence: “If you want to keep yourself and your 
kidney healthy, there is no other option than to follow the medication regimen. Everyone is 
responsible for his/her own health.” (Female, 46). Adherence was described as a sense of 
gratitude and obligation towards the donor: “I have to take care of my kidney, otherwise I 
would feel guilty towards my donor, who gave me a chance of living.” (Female, 45). One 
patient identified being free from dialysis as the most important motivator to adhere to his 
medication: “I take the disadvantages of my medication for granted, as long as I don’t have to 
go back on dialysis.” (Male, 61).  
  Secondly, patients were asked about the ways in which they integrate the ISM regimen 
into their daily lives. They emphasized that medication use is an integral part of their daily 
lives. In general, they expressed that they have no problems with integrating the ISM into 
their daily lives. Participants were asked to report strategies they use to remember to take their 
medication. Strategies that are implemented, are pillbox use, alarm systems, and being 
reminded by their spouse. Three out of 15 patients (20%) reported some form of non-
adherence. The only reason for non-adherence that was mentioned, was forgetfulness. Patients 
who mentioned having not taken their medication on schedule, explained that they missed it 
while going out for dinner and taking it some hours later, despite setting an alarm. The non-
adherence that was reported by the patients was thus merely unintentional. 
  Thirdly, we asked if patients had experienced side effects from the ISM, and if so, how 
they consider these relative to the benefits of ISM. Several side effects of the ISM were 
mentioned by the patients. Almost half of the participants (7 out of 15) experienced one or 
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more side effects up until the time of the interview, namely excessive sweating, swollen legs 
and feet, neuropathy (e.g. trembling), skin problems (e.g. rashes, skin cancer), and fatigue. 
Four patients experienced side effects at the time of the interview. Some participants 
mentioned that the side effects place a burden on their daily activities. For example: “I used to 
be a sports fanatic, and now I can only do some light fitness exercises due to my low 
haemoglobin values.” (Male, 47). Only two participants reported psychological distress as a 
consequence of the side effects. A quote that illustrates this: “My excessive sweating is really 
embarrassing, and I usually carry an extra shirt during the day. However, my health is more 
important than aesthetics.” (Male, 51). There was consensus about the benefits of  ISM 
outweighing the disadvantages of ISMs. A woman (44 years old) explained: “The side effect 
that worries me the most is skin cancer. I’ve had several spots removed, and I constantly have 
to check my skin. However, it doesn’t possess my life, and it doesn’t outweigh the importance 
of reducing the risk of graft rejection with my medication.” 
  Finally, we asked if patients worry about the risk of graft rejection, and if this affects 
their medication-taking behaviour. Surprisingly, only one patient expressed to be concerned 
about the risk of graft rejection: “worries about graft rejection strongly influence my daily 
life; I am constantly thinking about how to reduce the risk of rejection, for example by 
washing my hands.” (Male, 46). Many patients expressed an adaptive way of coping with the 
risk of transplant rejection. They mentioned that being worried about the possibility of graft 
rejection would only limit their ability to lead a healthier life. For example, a man (51 years 
old) explained that “you shouldn’t allow the disease to be the center of your life. I do what is 
in my abilities to control my condition, and in the meantime I live every day to the fullest.  
I don’t see a sense of living in fear and sadness”. Another patient mentioned: “By now I have 
no reason to worry about rejection, as I feel fine and my lab values are good” (Female, 45). 
  In summary, patients were aware of their condition and the importance of ISM, and 
took their health seriously. Adherence to ISM was perceived as a strategy to manage the risk 
of graft rejection. Interestingly, forgetfulness was the only reason that was mentioned for non-
adherence; no intentional non-adherence was reported by the participants. Several side effects 
were experienced, which were quite severe in some cases. However, only two patients 
expressed to be worried about actual or possible side effects. There was unanimity about the 
benefits and necessity of medication, which surpass (potential) side effects and their 
consequences. Finally, the results indicated that worries about graft rejection played a minor 
role in these patients’ daily lives.  
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              Discussion 
 
Non-adherence to ISM among renal transplant recipients poses a serious health risk, as it is 
associated with a 7 times higher risk of graft rejection (Butler et al., 2004). Considering this,  
it is of great importance to identify the risk factors that are associated with medication 
adherence in this patient group. This cross-sectional study consisted of a quantitative part  
(a questionnaire) and a qualitative part (an interview). In the quantitative part of this study, we 
firstly aimed to classify and describe self-reported medication adherence across a sample of 
renal transplant recipients within 1.5 years after transplantation. In this sample, 30.8% of 39 
participants was classified as non-adherent. This result is comparable to some previous studies 
using a self-report scale (Chisholm-Burns et al., 2012; Massey et al., 2013), but higher than 
others (Weng et al., 2010; Weng et al., 2017). A few studies reported an even higher level of 
non-adherence than the rate that was found in our sample (Lennerling & Forsberg, 2012; Silva 
et al., 2016). These differences could be explained by the use of different self-report scales 
and methods to assess non-adherence, such as collateral reports and measuring blood levels of 
immunosuppressant medication, or a combination of these methods. 
  The second aim of our study was to compare adherent and non-adherent patients on 
age, gender, educational level, time post-transplant, amount of ISM medications per day and 
amount of ISM pills per day (as a measure of complexity of the regimen), and certain 
psychological factors. Across this sample, we failed to find a significant relationship between 
adherence classification and these sociodemographic and clinical variables. These results are 
in contrast with the majority of the studies that have been described in the meta-analyses of 
DenHaerynck et al. (2005) and Rebafka (2016). As amount of ISM pills per day was not 
normally distributed, this variable was not included in our analyses. 
   With regard to the psychological factors, self-efficacy regarding disease management 
was very high, with a mean of 7.47 out of 9. This result implicates that participants in this 
sample had strong beliefs regarding their abilities to manage their condition, e.g. having 
knowledge of their disease and managing signs and symptoms. Previous studies have 
indicated that self-efficacy is important for self-care behaviours among renal transplant 
recipients, which is in accordance with the Health Belief Model (Denhaerynck et al., 2007; 
Silva et al., 2016; Weng et al., 2010; Wierdsma et al., 2011). However, in this study we failed 
to find a significant relationship between self-efficacy and adherence group classification.  
  With regard to medication beliefs, perceived necessity of ISM was strong in this 
sample, with a mean score of 4.28 out of 5. This finding suggests that patients place a high 
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value of their ISM on their (future) health. The average score on medication-related worries 
was 2.85 out of 5, which corresponds with ‘neutral’. Previous studies have found that high 
perceived medication necessity and low medication-related worries predict medication 
adherence among kidney transplant recipients, supporting the necessity-concern framework 
(Chisholm-Burns, 2012; Kung et al., 2012). This study failed to support these findings. 
Butler, Peveler, et al. (2004) suggested that the absence of an association between medication-
related worries and adherence may be explained by the stronger impact of transplant-related 
worries (i.e. fear of great rejection), and that this area should be further studied. In our sample, 
the average transplant-related worry score was fairly high (3.39 out of 5), which indicates that 
patients were worried about the risk of graft rejection. However, no significant differences 
between adherent and non-adherent patients on transplant-related worries were found. This 
contradicts the findings of Griva et al. (2012) and Orr et al. (2007), who suggested that high 
transplant-related worries are a motivational factor for medication-taking behaviour. 
Moreover, our goal was to examine the predictive power of the combination of self-efficacy, 
medication beliefs and transplant-related worries for self-reported ISM adherence, as these 
factors are modifiable and may be important to target in the clinical setting. The effect of our 
model failed to reach significance, which indicates that the variation in adherence scores 
cannot be explained by the combination of these variables. 
  Thirdly, our aim was to examine the relation between medication- and transplant-
related worries. Contrary to our expectation, the relation between these types of worries was 
found to be non-significant. However, the correlation coefficient of .30 can be interpreted as a  
medium effect size, which is promising. Future studies have to create a better understanding 
of types of worry that play a role in the daily lives of kidney transplant recipients, and their 
effect on ISM adherence. 
  There may be several explanations for the absence of significant results in the 
quantitative part of this study. Due to weak P values we failed to reject the null hypothesis, 
which states that differences between groups are due to chance alone. However, we found 
medium effect size values, of .42 and .43 for self-efficacy and time post-transplant, 
respectively. For these variables, mean differences between groups were almost half a 
standard deviation. Due to the small sample size, there was a low statistical power (i.e. the 
chance of correctly accepting the alternative hypothesis) of 22.66%. As a result, the 
probability of making a Type II error (i.e. accepting the null hypothesis when in reality the 
alternative hypothesis is true) was high (77%). In theory, with subgroup sample sizes of 65 
and 130 would be required to reach a power of 80% (with a significance level of .05) and 
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Cohen’s d of .40. In light of this, it is likely that we would have found a significant relation 
between adherence and these two variables with a larger sample size. However, future studies 
should be conducted in order to confirm this assumption. 
In addition to the small sample size, dichotomization of adherence scores may have also 
caused a lack of statistical power due to a loss of information that is associated with this 
procedure (Federov, Mannino, & Zhang, 2009). It should, however, be noted that most studies 
that we found, used dichotomization. Another possible explanation for the absence of 
significant outcomes in this study, is the fact that the psychological factors we selected are not 
exhaustive. Many other factors may play a role in medication taking behaviour, such as 
coping style, perceived autonomy in the management of disease and treatment (Gremigni et 
al., 2007), and the presence of anxiety and depression (DiMatteo, Lepper, & Croghan, 2000). 
  In the second part of our study, a different sample from the same population was 
interviewed to acquire more in-depth information on experiences with regard to the ISM 
regimen, and the relation between adherence and beliefs regarding medication and the graft. 
Moreover, we explored additional reasons for medication (non-)adherence from the patient 
perspective that were not integrated in the questionnaire. The high perceived necessity of ISM 
is comparable with the findings from our questionnaire survey. All participants perceived 
adhering to the ISM regimen as a way to cope with the risk of graft rejection, despite the 
possible negative consequences of these medicines. Another frequently mentioned reason to 
adhere, was being free from dialysis. This finding corresponds with the results of a study of 
Muduma et al. (2016), who conducted semi-structured interviews in focus groups. Many of 
the patients in their study perceived living with a strict medication regimen and side effects as 
a price worth paying to be free from dialysis. In our sample, 20% of the patients reported 
some form of non-adherence. We had the impression that – although adherence was measured 
in different ways – this number was somewhat comparable to the results of the questionnaire. 
Interestingly, only unintentional adherence was reported in this sample, which corresponds 
with a study of Griva et al. (2012). This finding would perhaps suggest that factors such as 
age and complexity of the regimen underlie medication-taking behaviour (Lehane & 
McCarthy, 2007). However, we did not find this in the quantitative study. Forgetfulness was 
the only reported reason for non-adherence in this sample, and seemed to be mostly related to 
disruptions in daily routine (e.g. going out for dinner or being too busy). Future research 
should focus on interventions that could help to reduce this type of non-adherence.   
Another important finding was that almost half of the patients had experienced side effects of 
ISM up until the time of the interview. None of the patients who were free from side effects 
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reported to be worried about possible future side effects. However, two patients, who were 
experiencing side effects at the time of the interview, reported shame and worry about these 
effects. Finally, we found that patients were generally not worried about the risk of graft 
rejection, which does not correspond with the findings from our questionnaire survey.  
    This study has several limitations that should be taken into account. As discussed 
before, the sample size was small, which may have led to insufficient power to find 
significant results. Moreover, the sample may not be representative for the population of 
kidney transplant recipients, as we recruited patients from a single centre who were able to 
understand Dutch. In addition, we had the impression that the health status of these patients 
may have been more stable as compared with patients who did not participate. Furthermore, 
the cross-sectional design of this study only allowed to look at adherence at one point in time. 
Future studies with longitudinal design are necessary to identify risk factors for non-
adherence. Another limitation of this study was the use of a single method to assess 
medication adherence (i.e. self-report). This may have given a distorted image of the actual 
adherence numbers in the sample. For instance, patients may have had the tendency to not 
score their medication taking behaviour with 100% on a VAS scale, as they do not perceive 
themselves as a “perfect patient”. This would implicate that we incorrectly identified patients 
as being non-adherent. Another possibility is that the findings are an underestimation of actual 
adherence rates due to socially desirable answers (Stirratt et al, 2015). Furthermore, the 
criteria for adherence in this study were very strict; any report of deviation from the regimen 
was classified as non-adherence. This classification is quite arbitrary, as there is no consensus 
about an optimal cut-off value for adherence (Nguyen, La Caze, & Cottrell, 2014). Moreover, 
it is not entirely clear what degree of nonadherence can cause transplant rejection (Moreso, 
Torres, Costa-Requena, & Serón, 2015). With regard to the qualitative part of this study, there 
was only one person who analysed the results, which may be a threat for the validity of the 
results. Finally, as with the quantitative part of this study, the validity of the findings may be 
negatively influenced by social desirability bias. Despite these limitations, this study has 
several strengths including a theoretical basis and the use of well-validated questionnaires.   
  To conclude, the results of this study implicate that a substantial number of kidney 
transplant recipients reported non-adherence of ISM. Despite the fact that we did not find 
significant relations between adherence and demographic, clinical, or psychological factors, 
we found promising effect size values with regard to the variables self-efficacy and time post-
transplant. The qualitative part of our study suggests that forgetfulness played an important 
role in non-adherence in this sample. Future studies with larger sample sizes and longitudinal 
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designs are needed to gain a better understanding of the impact of self-efficacy and time post-
transplant on adherence, and to examine the consequences of non-intentional adherence and 
interventions to reduce forgetfulness of ISM intake. 
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